Nanotechnology Now - Press Release: CombiMatrix Corporation Retires All Remaining Convertible Debt

Home > Press > CombiMatrix Corporation Retires All Remaining Convertible Debt

Abstract:
CombiMatrix Corporation (Nasdaq:CBMX) announced today that it has fully repaid the secured convertible debenture held by YA Global Investments, L.P., which had an original principal amount of $10.0 million.

CombiMatrix Corporation Retires All Remaining Convertible Debt

Mukilteo, WA | Posted on March 3rd, 2010

As a result of retiring this debt, the potentially dilutive reserve of approximately 1.1 million shares of common stock that could have been issued from conversion of the remaining debt was also retired.

"Retiring this debt strengthens our overall financial position and better positions CombiMatrix for future growth as well as attaining our strategic objectives," stated Scott Burell, Chief Financial Officer and Treasurer of CombiMatrix Corporation.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the recent economic slowdown affecting technology companies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Our periodic and other SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.

####

About CombiMatrix
CombiMatrix Corporation is a diversified biotechnology business that develops proprietary technologies, including products and services in the areas of drug development, genetic analysis, molecular diagnostics, nanotechnology and defense and homeland security markets, as well as in other potential markets where our products and services could be utilized. The technologies we have developed include a platform technology to rapidly produce user-defined, in-situ synthesized, oligonucleotide arrays for use in identifying and determining the roles of genes, gene mutations and proteins. Other technologies include proprietary molecular synthesis and screening methods for the discovery of potential new drugs.

Combimatrix Molecular Diagnostics, Inc. ("CMDX"), our wholly owned subsidiary located in Irvine, California, operates as a diagnostics reference laboratory that provides genetic diagnostics services to physicians, hospitals and clinics. CMDX provides its services through the use of arrays that utilize bacterial artificial chromosomes ("BACs") that enable genetic analysis. This type of technology is generally known as aCGH (or, array-Comparative Genomic Hybridization), and enables the analysis of gross genetic anomalies. CMDX also sells BAC array slides to labs outside the U.S. In addition, CMDX utilizes other non-proprietary technologies and products to augment its laboratory services in aCGH as well as ancillary services.

Leuchemix Inc. ("Leuchemix"), a minority owned subsidiary, is developing a series of compounds to address a number of oncology-related diseases. Leuchemix's first compound has entered initial clinical trials in the United Kingdom.

Additional information about CombiMatrix Corporation is available at www.combimatrix.com or by calling 1-800-985-CBMX (2269). Additional information about CMDX is available at www.cmdiagnostics.com or by calling 1-800-710-0624.

For more information, please click here

Contacts:
CombiMatrix Corporation
Amit Kumar, Ph.D., President & CEO
(425) 493-2000
Fax (425) 493-2010
Hayden IR

Investor Relations Contact:
Jeffrey Stanlis, Partner
(602) 476-1821

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark: